Biopharma Cred. Regulatory News (BPCR)

16 JULY 2020

BIOPHARMA CREDIT PLC

(THE "COMPANY")

COMPLETION OF SHARE BUYBACK PROGRAMME

Further to its announcement of 22 June 2020, BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, announces that its shares have traded at an average discount of 1% or less to the Net Asset Value per Ordinary Share over the most recent 2 week rolling period. Pursuant to the terms of the Prospectus, the Company will henceforth cease to repurchase its shares in the market as part of its discount control mechanism.

Since the activation of the discount control mechanism, as part of its Prospectus commitment the Company has repurchased a total of 59,694 shares representing 0.004% of its issued share capital as at 22 June.

Enquiries

BioPharma Credit plc

via Link Company Matters Limited

Company Secretary

+44 (0)1392 477 509

J.P. Morgan Cazenove

+44 (0)20 7742 4000

William Simmonds

Oliver Kenyon

Buchanan

+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com

David Rydell

Mark Court

Jamie Hooper

Henry Wilson

Notes to Editors

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24